The FDA approved fam-trastuzumab derextecan-nki (Enhertu; Daiichi Sankyo, Inc), a HER2-directed antibody-drug conjugate (ADC), in combination with pertuzumab as a first-line treatment for patients ...

FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...

The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line ...

AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or ...

FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo ...

AstraZeneca (AZN.L, AZN.ST) on Monday said Enhertu plus pertuzumab won approval in the US as the first-line treatment of ...

The Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki, or Enhertu from Daiichi Sankyo (DSNKY), in combination with pertuzumab for the first-line treatment of adults with ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki improved outcomes compared with capecitabine-based regimens as third-line treatment for certain patients with HER2-positive metastatic breast cancer, ...

Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine among ...

TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s trastuzumab deruxtecan has been recommended for conditional marketing authorization in ...